BR112023027025A2 - Métodos de uso de inibidores da aldosterona sintase - Google Patents
Métodos de uso de inibidores da aldosterona sintaseInfo
- Publication number
- BR112023027025A2 BR112023027025A2 BR112023027025A BR112023027025A BR112023027025A2 BR 112023027025 A2 BR112023027025 A2 BR 112023027025A2 BR 112023027025 A BR112023027025 A BR 112023027025A BR 112023027025 A BR112023027025 A BR 112023027025A BR 112023027025 A2 BR112023027025 A2 BR 112023027025A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- aldosterone synthase
- synthase inhibitors
- subject
- compound
- Prior art date
Links
- 229940123338 Aldosterone synthase inhibitor Drugs 0.000 title abstract 2
- 229940125904 compound 1 Drugs 0.000 abstract 2
- 208000016998 Conn syndrome Diseases 0.000 abstract 1
- 101000761956 Homo sapiens Cytochrome P450 11B2, mitochondrial Proteins 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000013846 primary aldosteronism Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163214521P | 2021-06-24 | 2021-06-24 | |
| US202163290364P | 2021-12-16 | 2021-12-16 | |
| PCT/US2022/073148 WO2022272300A1 (en) | 2021-06-24 | 2022-06-24 | Methods of using aldosterone synthase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023027025A2 true BR112023027025A2 (pt) | 2024-03-12 |
Family
ID=84545863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023027025A BR112023027025A2 (pt) | 2021-06-24 | 2022-06-24 | Métodos de uso de inibidores da aldosterona sintase |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240277698A1 (https=) |
| EP (1) | EP4358959A4 (https=) |
| JP (1) | JP2024523559A (https=) |
| KR (1) | KR20240035483A (https=) |
| AU (2) | AU2022299103B2 (https=) |
| BR (1) | BR112023027025A2 (https=) |
| CA (1) | CA3223211A1 (https=) |
| IL (1) | IL309428A (https=) |
| MX (1) | MX2023015121A (https=) |
| WO (1) | WO2022272300A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024310688A1 (en) * | 2023-06-29 | 2026-01-29 | AstraZeneca Ireland Limited | Crystal form of baxdrostat, and preparation method therefor and use thereof |
| CN121712504A (zh) * | 2023-07-27 | 2026-03-20 | 矿物疗法公司 | 用洛伦司他及两种或更多种降压药的组合治疗高血压的方法 |
| TW202525278A (zh) * | 2023-12-15 | 2025-07-01 | 愛爾蘭商阿斯特捷利康愛爾蘭有限公司 | 治療慢性腎病及高血壓之方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4777896A (en) * | 1995-02-10 | 1996-08-27 | G.D. Searle & Co. | Use of low dose amount of spironolactone for treatment of cardiovascular disease |
| US20070196510A1 (en) * | 2006-02-17 | 2007-08-23 | Gerber Michael J | Method for treating resistant hypertension |
| US9353081B2 (en) * | 2011-09-23 | 2016-05-31 | Hoffmann-La Roche Inc. | Bicyclic dihydroquinoline-2-one derivatives |
-
2022
- 2022-06-24 WO PCT/US2022/073148 patent/WO2022272300A1/en not_active Ceased
- 2022-06-24 MX MX2023015121A patent/MX2023015121A/es unknown
- 2022-06-24 BR BR112023027025A patent/BR112023027025A2/pt unknown
- 2022-06-24 JP JP2023579554A patent/JP2024523559A/ja active Pending
- 2022-06-24 CA CA3223211A patent/CA3223211A1/en active Pending
- 2022-06-24 AU AU2022299103A patent/AU2022299103B2/en active Active
- 2022-06-24 US US18/569,853 patent/US20240277698A1/en active Pending
- 2022-06-24 IL IL309428A patent/IL309428A/en unknown
- 2022-06-24 EP EP22829524.2A patent/EP4358959A4/en active Pending
- 2022-06-24 KR KR1020247002601A patent/KR20240035483A/ko active Pending
-
2026
- 2026-03-16 AU AU2026201954A patent/AU2026201954A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4358959A1 (en) | 2024-05-01 |
| WO2022272300A1 (en) | 2022-12-29 |
| AU2022299103A1 (en) | 2024-01-25 |
| KR20240035483A (ko) | 2024-03-15 |
| IL309428A (en) | 2024-02-01 |
| AU2022299103B2 (en) | 2025-12-18 |
| US20240277698A1 (en) | 2024-08-22 |
| AU2026201954A1 (en) | 2026-04-02 |
| JP2024523559A (ja) | 2024-06-28 |
| EP4358959A4 (en) | 2025-05-14 |
| CA3223211A1 (en) | 2022-12-29 |
| MX2023015121A (es) | 2024-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023027025A2 (pt) | Métodos de uso de inibidores da aldosterona sintase | |
| BR112022008858A2 (pt) | Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer | |
| BR112023015210A2 (pt) | Inibidores de cdk2 e métodos de uso dos mesmos | |
| BR112023014751A2 (pt) | Combinação de um inibidor de tead de 3-(imidazol-4-il)-4-(amino)-benzenossulfonamida com um inibidor de egfr e/ou inibidor de mek para uso no tratamento de câncer de pulmão | |
| BR112016027041A8 (pt) | combinações farmacêuticas para tratamento do câncer | |
| BR112022022634A2 (pt) | Inibidores de atr para o tratamento de câncer | |
| BR112012010705A2 (pt) | composto, composição farmacêutica, produto farmacêutico combinado, uso de um composto, e, métodos para tratar uma doença ou condição, e para inibir um bromodomínio | |
| BR112020015915A8 (pt) | Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer | |
| BR0304648A (pt) | Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia | |
| BR112013010310A2 (pt) | inibidores de acetil-coa carboxilase de lactama n1/n2 | |
| BR112015009168A2 (pt) | composto de fórmula estrutural xi, uso de um composto, composição farmacêutica, método de tratamento de uma doença mediada pela pde4 em um sujeito, método de modulação de uma função mediada pela pde4 em um sujeito, método de alcançar um efeito em um paciente e método para inibir a pde4 | |
| BR112023023527A2 (pt) | Inibidores de nlrp3 | |
| BRPI0611923A2 (pt) | modulaÇço sinergica da ftl3 quinase usando os moduladores de quinase aminoquinolina e aminoquinazolina | |
| BR112022000713A2 (pt) | Imidazopirimidinas como inibidores de eed e o uso das mesmas | |
| NO20091810L (no) | Sammensetninger, set og anvendelser for beskyttelse av huden mot patogene mikroorganismer | |
| BR112012004453A8 (pt) | composto inibidor de proteína quinase, sua composição farmacêutica e seu uso | |
| BR112012021659A2 (pt) | composto, composição farmacêutica, método para tratar e/ou prevenir distúrbios e doenças. | |
| BR112012024822B8 (pt) | Composto, uso de um composto e composição farmacêutica | |
| BR112023025916A2 (pt) | Combinação de um inibidor de braf e um inibidor de mek, uso de uma combinação, método para o tratamento ou profilaxia de câncer, composições farmacêuticas e invenção | |
| CL2022000835A1 (es) | Inhibidor de diacilglicerol aciltransferasa 2 | |
| BR112022022305A2 (pt) | Combinação farmacêutica que compreende tno155 e nazartinibe | |
| BR112022001054A2 (pt) | Inibidores enzimáticos | |
| BR112022001390A2 (pt) | Inibidores de enzima | |
| EA202190776A1 (ru) | Комбинация маломолекулярных ингибиторов cd-47 с другими противораковыми агентами | |
| BR112023026538A2 (pt) | Pirazóis com pirimidinil substituído como inibidores de cdk2 |